YahooOctober 2, 2026 at 8:15 AM NY25 Days Ago
Will Camzyos Growth Keep Driving BMY's Cardiovascular Portfolio?
Bristol Myers' Camzyos gains a broader FDA label and strong sales growth, while emerging competitors and pipeline setbacks shape its cardiovascular outlook.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Yahoo
